Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of 5.27 HKD per share based on a 14x PE valuation for 2025E [9]. Core Insights - The company reported total revenue of 21.49 billion RMB for 2024, reflecting a year-on-year increase of 0.2%, and a net profit attributable to shareholders of 861 million RMB, up 3.36% year-on-year. The second half of the year showed significant revenue growth improvement, driven by average price increases despite a decline in sales volume [2][8]. - The gross profit margin increased by 2.61 percentage points to 37.79%, with gross profit rising by 7.65% year-on-year. The sales expense ratio increased due to heightened market competition and promotional spending [2][8]. - The company is focusing on restructuring to enhance customer experience and operational efficiency, with notable performance in the soda and functional drinks categories [2][8]. Financial Data and Forecast - Total revenue projections for 2025-2027 are 23.13 billion RMB, 24.62 billion RMB, and 26.05 billion RMB, respectively. Net profit attributable to shareholders is expected to be 975 million RMB, 1.10 billion RMB, and 1.24 billion RMB for the same years, with corresponding EPS of 0.35 RMB, 0.39 RMB, and 0.44 RMB [2][5][8]. - The company achieved revenue of 16.37 billion RMB in the soda category for 2024, a year-on-year increase of 2.50%, maintaining the leading market share [3][8]. - The juice category reported revenue of 3.13 billion RMB, down 7.46% year-on-year, focusing on profit packaging development [3][8]. Business Strategy and Performance - The company is optimizing its customer structure and marketing network, achieving significant growth in direct sales and maintaining a controllable business revenue ratio of approximately 90% [4][5]. - The smart retail business has shown rapid revenue growth, and the COFCO Enjoy Club has also seen revenue increases with improved average product prices [2][8]. - The company is expanding its product offerings, including new packaging for soda and innovative marketing strategies targeting younger consumers [3][4][8].

Investment Rating - The report maintains an "Outperform" rating for DPC Dash [2][6][13] Core Views - DPC Dash reported a revenue of RMB 4.31 billion for 2024, representing a 41% year-on-year increase, with a gross profit margin of 72.9% [3][12] - The company achieved a same-store sales growth (SSSG) of 2.5%, marking 30 consecutive quarters of positive growth [4][12] - The adjusted net profit for 2024 was RMB 131 million, with an adjusted net profit margin of 3.0%, up 2.7 percentage points year-on-year [5][12] Financial Performance Summary - Revenue projections for 2025-2027 are RMB 5.44 billion, RMB 7.03 billion, and RMB 8.78 billion, respectively, with adjusted net profits of RMB 188 million, RMB 340 million, and RMB 492 million [6][11][13] - The company plans to open 300 new stores in 2025, following a net addition of 240 stores in 2024, bringing the total to 1,008 stores [4][12] - Membership program growth is notable, with a total of 24.5 million members by the end of 2024, contributing 64.5% to revenue [4][12] Valuation and Target Price - The target price is set at HKD 125.9, reflecting a valuation of 2.5-3 times the price-to-sales ratio for 2025 [2][6][13] - The report indicates a significant increase in target price from a previous estimate of HKD 79.4, highlighting the company's strong growth potential [6][13]

Economic Overview - In February 2025, Indonesia's CPI decreased by 0.09% year-on-year, marking the first annual deflation since March 2000[2] - Thailand's CPI increased by 1.08% year-on-year, slightly below the expected 1.10%[25] - Vietnam's CPI rose by 2.91% year-on-year, the lowest level in three months[41] Consumer Confidence - Indonesia's consumer confidence index fell to 126.4 in February 2025, down from 127.2 in January, reflecting concerns over declining purchasing power[20] - Thailand's consumer confidence index improved to 57.8 in February 2025, up from 54.2 in the previous year, driven by government stimulus and tourism recovery[27] Stock Market Performance - Only Vietnam and Singapore's stock markets closed higher in February 2025, while Indonesia, Thailand, and Vietnam's consumer sectors outperformed the broader market[3] - The STI index in Singapore reached a historical high of 3934 points in mid-February due to government stimulus measures[3] Valuation Trends - As of February 2025, the historical valuation levels for essential consumption in Indonesia were at 5%, while Thailand's were at 1% for essential and 64% for discretionary consumption[4] - Vietnam's essential consumption valuation improved to 28%, contrasting with declines in other markets[4] Retail Index Data - In February 2025, Indonesia's retail index was reported at 211.3, while Singapore's was at 122.8, and Malaysia's at 184.9[8]

Investment Rating - The report maintains an "Outperform" rating for the company [2][7][16] Core Insights - The company is driven by dual-engine growth through partnerships and commercial sales, achieving key milestones in 2024 [4][14] - The company reported FY24 revenue of RMB 430 million, a 20.9% increase, with drug sales of RMB 35.94 million and business development revenue of RMB 390 million [12][3] - The gross profit reached RMB 420 million, reflecting a 31.1% increase, with a gross margin of 97.2% [12][3] - R&D expenses totaled RMB 740 million, representing 171.7% of revenue, indicating a strong commitment to innovation [12][3] - The company has a robust commercial team of over 300 employees, effectively covering more than 1,100 hospitals across 220+ cities [13][3] Financial Performance - Revenue projections for 2025 and 2026 have been adjusted to RMB 700 million and RMB 1.2 billion, respectively, indicating year-on-year growth of 63.2% and 71.7% [16][7] - The company is expected to incur net losses of RMB 580 million and RMB 550 million for 2025 and 2026 [16][7] - The DCF valuation model suggests a target price of HKD 70.75 per share, reflecting a positive outlook [16][7] Product Development and Pipeline - CM310 has been approved for three indications and is expected to achieve RMB 500 million in sales this year [18][5] - CMG901 is in a global Phase III trial and shows promising results, positioning it to be the first approved CLDN18.2 ADC [18][5] - The company has established Newco collaborations for several projects, expected to generate significant upfront and milestone payments [18][5] R&D Capabilities - The company has a diverse R&D platform with multiple novel molecules in clinical stages, including CM336 and CM350 [15][6] - The TCE platform is advancing steadily, with several molecules showing preliminary positive efficacy [15][6] - The company is expanding into innovative RNA-based therapeutics, reflecting its commitment to cutting-edge research [15][6]

Investment Rating - The report maintains an "Outperform" rating for Sichuan Kelun-Biotech Biopharmaceutical with a target price of HKD 297.20, reflecting an upward revision of 48.5% from the previous target price of HKD 200.1 [2][22]. Core Insights - The company has entered a phase where R&D collaboration revenue and commercial sales serve as dual growth drivers, with a sales team expanding to 360 members by the end of 2024 [4][15]. - The company reported a revenue of RMB 1.93 billion for 2024, a 25.5% year-over-year increase, with a gross profit of RMB 1.27 billion and a gross margin of 65.9%, up 16.6 percentage points [3][14]. - Regulatory and R&D catalysts are expected to be abundant in 2025, with three NDAs submitted that are likely to be approved within the year, contributing to incremental revenue growth [5][19]. Financial Performance - Revenue forecasts for 2025-2027 have been adjusted to RMB 1.96 billion, RMB 2.98 billion, and RMB 4.47 billion, reflecting year-over-year growth of +1.4%, +52.2%, and +49.9% respectively [21]. - The net profit forecast for 2025-2027 has been revised to -RMB 280 million, RMB 240 million, and RMB 1.02 billion, showing a significant improvement from previous estimates [21]. - As of December 31, 2024, the company had cash and financial assets of RMB 3.08 billion, reflecting a 21.6% year-over-year increase [3][14]. Product Pipeline and Market Potential - The company has three approved products covering five indications, with ongoing clinical trials for SKB264 and other promising molecules in its pipeline [4][16]. - SKB264 has seen steady sales growth since its market launch in November 2024, with peak sales estimated to reach USD 6-7 billion [16]. - A167, the first PD-L1 inhibitor approved for nasopharyngeal carcinoma, holds significant commercial potential due to the high prevalence of the disease in China [17]. Valuation Methodology - The valuation is based on a DCF model with a weighted average cost of capital of 9.4% and a terminal growth rate of 3.5%, leading to a target price of HKD 297.20 per share [22].

Investment Rating - The report maintains an "Outperform" rating for China Resources Pharmaceutical [3][19] Core Insights - In FY24, the company achieved revenue of CNY 257.7 billion, representing a year-on-year growth of 5.3%, with contributions from pharmaceutical manufacturing, distribution, and retail segments at 16.1%, 80.0%, and 3.9% respectively [4][15] - The gross profit margin (GPM) was 15.8%, an increase of 0.1 percentage points year-on-year, primarily driven by improvements in the pharmaceutical manufacturing segment [4][15] - The attributable net profit for FY24 was CNY 3.35 billion, a decrease of 13.1% year-on-year, mainly due to increased minority interests following the equity restructuring of China Resources Zizhu [4][15] Revenue Breakdown - Pharmaceutical Manufacturing: Revenue reached CNY 46.3 billion, up 6.6% year-on-year, with traditional Chinese medicine, chemicals, biological drugs, and nutritional supplements showing growth rates of +12.2%, +2.8%, +3.3%, and -11.8% respectively [5][16] - Distribution: Revenue was CNY 213.2 billion, reflecting a 5.5% year-on-year increase, with a stable GPM of 5.9%. The company has strengthened channel partnerships and expanded digital healthcare services [5][17] - Retail: Revenue amounted to CNY 10.1 billion, also up 5.5% year-on-year, driven by a 17% increase in high-value drug direct-to-patient (DTP) business [6][18] Financial Forecasts - Revenue forecasts for FY25 and FY26 have been slightly adjusted to CNY 278.6 billion and CNY 299.2 billion, respectively, reflecting growth rates of 7.3% and 5.8% [8][19] - Attributable net profit forecasts for FY25 and FY26 are now CNY 4.3 billion and CNY 4.8 billion, corresponding to growth rates of 27.4% and 11.8% [8][19] - The target price is set at HKD 6.97, based on a 2025 P/E ratio of 11.0x [8][19]

Investment Rating - The report maintains an "Outperform" rating for Yum China Holdings [5][11]. Core Insights - Yum China Holdings reported a revenue of 11.30 billion USD for 2024, reflecting a 3% year-over-year growth, with an adjusted net profit of 911 million USD, up 8% year-over-year [2][11]. - In Q4 2024, the company achieved a revenue of 2.60 billion USD, a 4% increase year-over-year, and an adjusted net profit of 115 million USD, marking an 11% growth year-over-year [2][11]. - The overall system sales for KFC and Pizza Hut grew by 5% and 3% respectively, while same-store sales declined by 1% and 2% [2][11]. - The company plans to add approximately 1,600 to 1,800 new stores in 2025, with capital expenditures estimated between 700 to 800 million USD [3][11]. Summary by Sections Financial Performance - For 2024, total revenue reached 11.30 billion USD, with a 3% year-over-year increase, and net profit was 911 million USD, up 8% year-over-year [6][11]. - Q4 2024 revenue was 2.60 billion USD, a 4% increase year-over-year, with an adjusted net profit of 115 million USD, reflecting an 11% growth year-over-year [2][11]. - The diluted EPS for Q4 2024 was 0.30 USD, a 30% increase year-over-year [2][11]. Restaurant Expansion and Performance - By the end of 2024, the total number of restaurants reached 16,395, with a net increase of 1,751 restaurants, representing a 12% annual growth [3][11]. - KFC had 11,648 stores, with a net increase of 1,352 stores (+13%), while Pizza Hut had 3,724 stores, with a net increase of 412 stores (+12%) [3][11]. - In Q4 2024, restaurant income was 2.43 billion USD, with a profit margin of 12.3%, an increase of 1.6 percentage points year-over-year [3][11]. Digital and Delivery Growth - By the end of Q4 2024, KFC and Pizza Hut had over 525 million members, with member sales accounting for 65% of total sales [4][11]. - Digital orders for 2024 reached 9.60 billion USD, representing 90% of restaurant income, while delivery sales grew by 14% year-over-year, making up 39% of restaurant income [4][11]. Shareholder Returns - The company returned 1.50 billion USD to shareholders in 2024, which is about 8.5% of its market capitalization [4][11]. - The cash dividend per share is set to increase by 50% to 0.24 USD [4][11]. Profit Forecast and Valuation - The net profit forecast for 2025-2027 is 950 million USD, 1.01 billion USD, and 1.07 billion USD, with growth rates of 4.3%, 5.9%, and 6.6% respectively [5][11]. - The target price is set at 431.8 HKD per share based on a 22x PE ratio for 2025 [5][11].

Investment Rating - The report maintains an "OUTPERFORM" rating for WuXi XDC Cayman, with a target price of HK$49.10 based on a current price of HK$41.90 [1][19]. Core Insights - WuXi XDC reported robust growth in 2024, with revenue reaching RMB4.052 billion, a year-on-year increase of 90.8%. The gross margin improved to 30.6%, up 4.3 percentage points, and net profit attributable to shareholders surged 277.2% to RMB1.070 billion [4][12]. - The company secured 53 new integrated projects and 23 iCMC projects in 2024, supporting clients in submitting 30 IND applications and delivering over 300 GMP production batches [5][13]. - North America emerged as the fastest-growing region, with revenue from North American clients reaching RMB2.03 billion, a 138.3% increase year-on-year, accounting for 50.1% of total revenue [15]. - The total backlog of orders reached RMB991 million, reflecting a 71% year-on-year growth, with new contract signings maintaining pace with this growth [16]. Financial Summary - Revenue projections for WuXi XDC from 2025 to 2027 are RMB5.587 billion, RMB7.387 billion, and RMB9.461 billion, representing year-on-year growth rates of 37.9%, 32.2%, and 28.1% respectively [7][18]. - Net profit attributable to shareholders is expected to be RMB1.342 billion, RMB1.818 billion, and RMB2.403 billion for the same period, with growth rates of 25%, 35%, and 32% respectively [10][18]. - The adjusted net profit is projected to be RMB1.550 billion, RMB2.010 billion, and RMB2.580 billion, with year-on-year growth rates of 32%, 30%, and 28% [10][18].

Investment Rating - The report maintains an "OUTPERFORM" rating for Pop Mart International [2][9][15] Core Views - The company achieved record revenue and profit, with revenue expected to approach RMB 100 billion [1][3] - The company is projected to continue strong growth, with revenue expected to exceed RMB 200 billion in 2025, driven by both domestic and international markets [3][9] Financial Performance Summary - For the fiscal year 2024, revenue reached RMB 13.04 billion, a 107% year-on-year increase, with a gross profit margin of 66.8%, up 5.5 percentage points [3][14] - Adjusted net profit for 2024 was RMB 3.4 billion, reflecting a 186% year-on-year growth, with an adjusted net profit margin of 26.1% [3][14] - The company expects revenue for 2025 to be RMB 22.1 billion, a 69% increase year-on-year, and adjusted net profit to reach RMB 6.3 billion, an 86% increase [9][15] Domestic Business Summary - Domestic revenue was RMB 7.97 billion, up 52% year-on-year, with significant growth in both offline and online channels [4][14] - The number of retail stores increased to 401, with a net addition of 38 stores [4][14] - Online sales grew by 77%, driven by increased customer engagement across various platforms [4][14] International Business Summary - International revenue surged to RMB 5.07 billion, a 375% increase year-on-year, with overseas revenue accounting for 39% of total revenue [5][14] - The company expanded its international presence, adding 50 retail stores and entering new markets including Vietnam, Indonesia, and Italy [5][14] - The gross profit margin for international operations was 71.3%, exceeding domestic levels [5][14] IP Development and Membership Growth - The company reported strong performance from its IPs, with revenue from major IPs exceeding RMB 1 billion each [7][14] - Membership numbers reached 46.08 million, a 34% increase year-on-year, contributing significantly to sales [7][14] Theme Park Business Summary - The theme park segment exceeded expectations in revenue and profitability, attracting a diverse visitor demographic [8][14] - The company plans to upgrade two-thirds of the park's area and initiate a second phase of construction by 2026 [8][14] Profitability and Valuation - The report projects adjusted net profit margins to improve to 28.6% in 2025 and 30.9% by 2027 [9][15] - The target price for the stock is set at HKD 158.2, based on a 30x PE valuation for FY25 [9][15]

Group 1: AI Data Centers - The AI data center sector is experiencing a "valuation bubble + geopolitical risk" pricing logic, with rising supply chain costs due to Trump's tariff policies[1] - Major tech companies plan to invest over $345 billion in AI infrastructure in 2025, with Microsoft alone investing $80 billion[16] - NVIDIA's Blackwell chip production is accelerating, with four major public cloud vendors purchasing 3.6 million units, capturing 92% of the global AI GPU market[18] Group 2: Industrial and Energy Equipment - The price index for aircraft engines and components in the U.S. was 273.188 in February 2025, stable month-on-month and up 6.2% year-on-year[2] - The price index for gas turbines increased by 5.35% year-on-year and 0.22% month-on-month in February 2025[63] - The price index for electric and special transformers was 433.246 in February 2025, stable month-on-month and up 1.07% year-on-year[48] Group 3: Infrastructure Investments - The U.S. is expected to invest an average of $44 billion annually in the power grid from 2023 to 2030, with total investment in distribution networks reaching $581.5 billion[21] - In 2025, China's State Grid and Southern Grid are projected to invest over 825 billion yuan, a significant increase from 2024[31] Group 4: Defense and Aerospace - The U.S. government defense price index was 117.187 in Q4 2024, stable quarter-on-quarter and up 3.2% year-on-year[44] - Raytheon Technologies (RTX) continues to benefit from increased defense spending, particularly in missile systems and aerospace electronics[5]